IRVINE, Calif.--(BUSINESS WIRE)--IDM Pharma, Inc. (Nasdaq: IDMI) announced today the completion of patient enrollment in two Phase II clinical trials of Uvidem, IDM’s therapeutic product for the treatment of melanoma being developed in collaboration with sanofi-aventis. Thirty-eight patients with malignant melanoma were included in the US study and 53 patients with resected stage II/III melanoma were included in the European study.
